Company results keep coming in the week ahead, though larger companies are tailing off, with the coming days seeing numbers from easyJet, Dr Martens and.
Scancell Holdings PLC - Nottingham, England-based cancer immunotherapies developer - Presents data from first stage of Phase 2 Scope trial at 20th International Congress of the Society for Melanoma.
Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) told investors that it has been selected for a poster presentation of data from the first stage of its Phase 2.
Key highlights for biotech group Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF)’s financial year ending 30 April 2023 included a positive data reading arising.